Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.53 |
| ▸ | BCHE | P06276 | 5/20 | 0.53 |
| ▸ | BACE1 | P56817 | 4/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607249 | 1.00 | ACHE (0.53) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL3273178 | 1.00 | ACHE (0.53) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL6646032 | 0.90 | CYP2D6 (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL311417 | 0.90 | ACHE (0.61) | ACHEBCHEBACE1CCR3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL312187 | 0.88 | ACHE (0.59) | ACHEBCHEBACE1CCR3ALDH1A1 | |
| SCHEMBL8790984 | 0.86 | LTA4H (0.56) | ACHECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5016797 | 0.84 | ACHE (0.54) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL6567147 | 0.82 | ROCK2 (0.47) | BCHELTA4HDRD2DRD4 | |
| SCHEMBL7226381 | 0.81 | ALDH1A1 (0.54) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL24027115 | 0.78 | FUCA1 (0.55) | ACHEBCHEBACE1CCR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230121952-A1 | COMPOUNDS | INFLAZOME LIMITED (IE) | 2023-04-20 | — | — | US | disclosed |
| EP-4107153-A1 | COMPOUNDS | Inflazome Limited (IE) | 2022-12-28 | — | — | EP | disclosed |
| CN-115362152-A | Compound (I) | 英夫拉索姆有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-109928971-A | The amino tetrahydro pyran class compound and application thereof that aryl replaces | 广东东阳光药业有限公司 | 2019-06-25 | — | — | CN | disclosed |
| US-8946422-B2 | 8-methoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2616071-A2 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| US-20120077794-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXSMITHKLINE LLC (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077794-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXSMITHKLINE LLC (US) | 2012-03-29 | — | — | US | disclosed |
| US-5834499-A | TREATING GASTROINTESTINAL DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| EP-0749966-A1 | 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
| US-5576320-A | 1-heteruarylazetidines and -pyrrolidines, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-11-19 | — | — | US | disclosed |
| US-5565474-A | 1-heteroarylazetidines and -pyrrolidines process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-10-15 | — | — | US | disclosed |
| US-5466828-A | Chiral 3-cyano-1-substituted-pyrrolidines | WARNER-LAMBERT COMPANY (US) | 1995-11-14 | — | — | US | disclosed |
| US-5410057-A | 1-heteroarylazetidines and -pyrrolidines | SANOFI (FR) | 1995-04-25 | — | — | US | disclosed |
| WO-1995001962-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 3-(1-AMINO-1,1-BISALKYLMETHYL)-1-SUBSTITUTED-PYRROLIDINES | WARNER-LAMBERT COMPANY (US) | 1995-01-19 | — | — | WO | disclosed |
| US-5347017-A | Process for chiral 3-(1-amino-1,1-bisalkylmethyl)-1-substituted-pyrrolidines | WARNER-LAMBERT COMPANY (US) | 1994-09-13 | — | — | US | disclosed |
| EP-0591030-A2 | 1-Heteroaryl-azetidines and -pyrrolidines as 5-HT3 agonists | SANOFI (FR) | 1994-04-06 | — | — | EP | disclosed |
| US-5198449-A | N-substituted alpha-arylazacycloalkylmethanamines and their use as cardiovascular agents | A. H. ROBINS COMPANY INCORPORATED (US) | 1993-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121952-A1 | COMPOUNDS | NLRP3, NOD1, PYCARD | ACHE 4203/4885BCHE 3881/4885BACE1 73/4885 |
| US-20120077794-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | MCHR1, MCHR2, MC1R | ACHE 4382/4885BCHE 3398/4885BACE1 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.